AstraZeneca and Dynavax extend asthma deal
This article was originally published in Scrip
Executive Summary
AstraZeneca and Dynavax have extended their research collaboration on developing novel therapies for the treatment of asthma and chronic obstructive pulmonary disease until July next year.